GlassScriptPhysician profile
Rahul Vikram Jaswaney
NPI 1811491699
$636.97
in general payments reported to CMS, 2019-2025
14 companies · $85.81 in 2025
The $85.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.54 · 2023: $49.34 · 2024: $467 · 2025: $85.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.80 |
| Education | $270.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $316.88 | 2024-2025 | Ensite, Triclip, Assurity |
| Actelion Pharmaceuticals US, INC. | $53.74 | 2024 | Uptravi |
| Abiomed | $31.72 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $29.70 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.44 | 2024-2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $23.95 | 2024 | Arcalyst |
| Novo Nordisk INC | $21.66 | 2024 | Wegovy |
| Medtronic, INC. | $21.02 | 2022 | |
| Impulse Dynamics (USA) INC. | $21.01 | 2025 | Optimizer |
| Amgen INC. | $19.64 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $19.46 | 2024 | Xarelto |
| Inari Medical, INC. | $18.96 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biosense Webster, INC. | $18.27 | 2025 | Nuvision Ice Catheter |
| Terumo Medical Corporation | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Jaswaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.